OBJECTIVE: A retrospective clinical study to evaluate the effect of transarterial infusion (TAI) chemotherapy and transarterial chemoembolization (TACE) on liver metastasis after gastric cancer resection. METHODS: The study recruited patients who underwent surgical resection for stage T 2 N 2 M 0 gastric adenocarcinoma without liver metastasis. Patients chose to receive either TAI or systemic chemotherapy, based on the advantages and disadvantages of each regimen as explained by physicians. Both regimens comprised 100 mg/m 2 oxaliplatin and 500 mg/m 2 fluorodeoxy uridine, administered via TAI or a peripheral vein, commencing 30 days postsurgery. Patients who developed liver metastasis during the 3year follow-up period were offered TACE. RESULTS: Mean time from gastric cancer diagnosis to liver metastasis was significantly longer in the TAI group (n = 13) than in the systemic chemotherapy group (n = 29); 944 ± 231 days versus 506 ± 77 days. Patients who received TACE (n = 32) had a partial remission rate of 46.9% and a median survival of 14.7 months after diagnosis of liver metastasis. CONCLUSIONS: Locoregional TAI chemotherapy was more effective in reducing liver metastasis after gastric cancer resection than conventional systemic chemotherapy. TACE is an effective treatment for liver metastasis.
Introduction
Gastric cancer is the second most frequent cancer in the world 1 and the third most common cancer in China. 2 Surgery is the mainstay of treatment for gastric cancer and complete resection offers the best chance of a cure for localized tumours. 3 Despite radical surgery, survival times are < 5 years 4 and the rates of locoregional or distant recurrence remain high. 3,5 -7 Between 40% and 60% of patients develop recurrence after resection with curative intent. 8 The high risk of relapse after surgery has driven the search for new strategies to prevent recurrence and improve survival for patients with gastric cancer. 6 The effectiveness of chemotherapy as an adjuvant therapy for gastric cancer has been the subject of intense clinical research, 7 but the role of postoperative chemotherapy (including chemoradiotherapy or intraperitoneal chemotherapy) is not well established and there is no standard treatment. 4, 9 Compared YY Wang, W Zhang, S Qian et al.
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with surgery alone, adjuvant chemotherapy has been shown to improve overall survival in some, but not all, studies. 10 -13 The liver is the most common site of metastasis from malignant gastrointestinal tumours. 14 Patients usually receive conventional systemic chemotherapy after gastric cancer resection because there are few adjuvant therapies available that target liver metastasis.
Locoregional transarterial infusion (TAI) chemotherapy, performed via the hepatic artery, has been shown to increase chemotherapeutic concentrations in the liver. 15, 16 The present study evaluated the effect of adjuvant TAI chemotherapy compared with conventional systemic chemotherapy on the development of liver metastasis in adult patients who had undergone resection for gastric adenocarcinoma. The effect of transarterial chemoembolization (TACE) on response rates was also evaluated in those patients who developed liver metastasis during follow-up.
Patients and methods

STUDY POPULATION
Sequential patients who underwent surgical resection for gastric cancer at the Zhongshan Hospital, Fudan University, Shanghai, China, between January 2005 and May 2008, were eligible for inclusion in this retrospective clinical study. All patients were diagnosed by gastroscopy and biopsy ≤ 1 week before surgery. Inclusion criteria were: surgical removal of the primary tumour; pathological confirmation of grade II / III adenocarcinoma; 17 focal lesion invading all layers of the gastric wall but not extragastric organs, with the exception of some perigastric lymph nodes at the time of the surgery; T 2 N 2 M 0 pathological stage 18 ; no evidence of liver metastasis at the time of surgery; no preoperative chemotherapy. Patients were excluded from the study if they had any of the following: severe and uncontrolled infection;  gastrointestinal obstruction; a history of other  types  of  malignancy  or  previous  chemotherapy; incomplete follow-up information (patient lost to follow-up or date of death not available).
The study protocol was approved by the Zhongshan Hospital Ethics Committee and all patients provided written informed consent prior to enrolment.
CHEMOTHERAPY
After surgical resection, the advantages and disadvantages of TAI and systemic chemotherapy (including treatment method ology, drugs used, side-effects, etc.) were objectively explained to each patient by a physician. Patients then chose between the two therapies without any further guidance and confirmed their choice in writing. Both types of chemotherapy were initiated 30 days after surgery.
Patients in the TAI group underwent coeliac angiography to exclude the presence of liver metastasis. TAI chemotherapy comprised three cycles of 100 mg/m 2 oxaliplatin and 500 mg/m 2 fluorodeoxyuridine (FUDR) on day 1 followed by 500 mg/m 2 FUDR on days 2 -5, each cycle separated by a 60-day interval. The catheter was placed in the coeliac trunk.
Patients in the systemic chemotherapy group received six cycles of 100 mg/m 2 oxaliplatin and 500 mg/m 2 FUDR via peripheral venous infusion on day 1, followed by 500 mg/m 2 FUDR on days 2 -5, each cycle separated by a 30-day interval.
FOLLOW-UP
Patients were followed-up every 2 months for 3 years from the date of surgery. Examinations included abdominal ultrasound, computed tomography (CT) or YY Wang, W Zhang, S Qian et al.
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magnetic resonance imaging (MRI) to determine the presence of liver metastasis or new extrahepatic metastases. Laboratory tests included complete blood count (CBC) and liver and kidney function parameters (serum total bilirubin, alanine transaminase, aspartate transaminase, creatinine and blood urea nitrogen levels).
TACE
Patients who developed liver metastasis were offered TACE regardless of their initial treatment assignment, using the following inclusion criteria: identification of liver metastasis by abdominal imaging; physical score ≤ 2 according to the 5-point Eastern Cooperative Oncology Group standard (0, fully active; 5, dead); 19 serum alanine transaminase and aspartate transaminase levels < 2 × the upper limit of normal (ULN; 75 U/l), serum total bilirubin levels < 1.5 × ULN (1 mg/dl); normal CBC, coagulation and kidney function.
Patients were examined by coeliac trunk angiography, and also by arterial angiography if the superior mesenteric and inferior phrenic arteries were found to be involved in the blood supply to the lesions. Local anaesthesia was induced with 3 -5 ml lidocaine for femoral artery catheterization. The major feeding artery to the liver metastasis was then catheterized and 100 mg/m 2 oxaliplatin and 500 mg/m 2 FUDR were administered by TAI. TACE was then immediately performed with an emulsion of 30 mg/m 2 theprubicin and lipiodol (usually 3 -5 ml, according to tumour size). A microcatheter was used when a standard catheter could not selectively reach the tumour-feeding artery, in order to protect the function of normal liver tissue. Patients were hospitalized for 5 -7 days after TACE, according to their condition. TACE was repeated every 6 weeks and continued until patients withdrew from treatment or severe adverse events were observed.
Patients received supportive treatment, including liver protection with Sadenosylmethionine and reduced glutathione, antiemetic medication, antacids, anti-inflammatories and therapy to increase white blood cell count (granulocyte colony-stimulating factor [G-CSF]) as required. Routine haematological and biochemical tests to assess CBC and liver and kidney function were performed in all patients 1 week before and 1 week after each TACE treatment. When haematological toxicity of grade III or above was observed, 20 TACE was suspended, patients were treated with G-CSF and blood counts were measured daily until toxicity decreased to less than grade I. TACE was then restarted. Adverse effects (including alopecia, peripheral nerve toxicity, nausea and vomiting, diarrhoea, neutropenia, thrombo cytopenia, elevated serum total bilirubin and elevated serum transaminase) were recorded, according to published criteria. 20 Individual treatment responses were classified according to published standards for solid tumours as complete remission, partial remission, stable disease or progressive disease. 21 Complete and partial remission were considered indicative of therapeutic efficacy.
STATISTICAL ANALYSES
The time from diagnosis of gastric cancer to detection of liver metastasis was evaluated using Kaplan-Meier survival analysis. The incidences of liver and extrahepatic metastases were compared between the two treatment groups using the χ 2 -test. Survival times after the occurrence of liver metastasis in patients who underwent TACE were calculated and evaluated using Kaplan-Meier survival analysis. Statistical analyses YY Wang, W Zhang, S Qian et al.
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were performed using SPSS ® statistical software, version 13.0 (SPSS Inc. Chicago, IL, USA) for Windows ® . A P-value of < 0.05 was considered to be statistically significant.
Results
The study included 42 patients who underwent surgical resection for gastric adenocarcinoma; 13 patients received TAI chemotherapy and 29 received systemic chemotherapy. There were no significant between-group differences in age, male to female ratio or location of the primary tumour (Table 1) .
Liver metastasis was diagnosed in 69.2% (9/13) of patients receiving TAI chemotherapy and in 100% (29/29) of patients receiving systemic chemotherapy (P = 0.006). The time from diagnosis of gastric cancer to detection of liver metastasis was significantly longer in the TAI group than in the systemic chemotherapy group (944 ± 231 days versus 506 ± 77 days, P = 0.049).
Of the patients in the TAI group who did not develop liver metastasis, two were diagnosed with coeliac lymph node metastasis and one with bladder metastasis; the fourth patient had neither liver nor extrahepatic metastases. Extrahepatic metastases developed in eight patients in the systemic chemotherapy group; seven were diagnosed before and one was diagnosed after the development of liver metastasis. Of these eight patients, five had portal lymph node metastasis that resulted in obstructive jaundice and three developed retroperitoneal lymph node metastasis. There was no significant difference between treatment groups in the incidence of extrahepatic metastases diagnosed before liver metastasis (23.1% [3/13] versus 24.1% [7/29]).
In the TAI group, six patients with liver metastasis refused any further therapy and the remaining three underwent TACE. No extrahepatic metastases were identified in these three patients during follow-up. All 29 patients in the systemic chemotherapy group underwent TACE. In total, these 32 patients received 119 cycles of TACE (median of four cycles). Across both treatment groups, 15 (9. 4%) had progressive disease. The median survival time after liver metastasis was 14.7 months (range 7 -37 months; Fig. 1 ). A summary of adverse events observed during TACE is shown in Table 2 . Grade III / IV neutropenia was observed in two patients who recovered following treatment with G-CSF. The symptoms of patients who experienced grade III / IV nausea and vomiting, elevated serum total bilirubin or elevated serum transaminases improved and laboratory test results returned to near normal levels following antiemetic treatment or liver protective therapy, as appropriate. A typical case of a 75-year-old man with unresectable liver metastasis who achieved partial remission following TACE is shown in Fig. 2 . 
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Discussion
Surgery is the only potentially curative treatment for localized gastric cancer, but prognosis remains poor and patients have a high risk of locoregional or distant recurrence. 22, 23 Adjuvant chemotherapy improves overall survival in some solid tumours, possibly by decreasing residual micrometastatic lesions. 24 Numerous randomized studies of adjuvant chemotherapy in gastric cancer have been performed, some of which have reported an overall survival benefit; 11, 25 others have failed to show any such advantage. 13, 26 There is no consensus on the role of adjuvant intraperitoneal chemotherapy because a consistent overall survival benefit has not been demonstrated in randomized trials. 3 The present retrospective study investigated the effect of adjuvant TAI chemotherapy and TACE on liver metastatic gastric adenocarcinoma, and showed that TAI chemotherapy was more effective in preventing liver metastasis than systemic chemotherapy. The time from diagnosis of gastric adenocarcinoma to liver metastasis was significantly longer, and the incidence of liver metastasis was significantly lower, in patients who received TAI chemotherapy compared with those who received systemic chemotherapy. There was no difference between the two groups in the incidence of extrahepatic metastases, however.
Analyses of metastases are difficult to interpret due to heterogeneity in chemotherapy regimens, clinical stage, time to adjuvant therapy and type of surgery. 3 The present study reduced some of this heterogeneity by including only patients whose primary lesions were fully resected, and who were diagnosed with grade II / III and stage T 2 N 2 M 0 gastric adenocarcinoma. In addition, all patients received the same chemotherapeutic regimens (comprising oxaliplatin and FUDR) beginning 30 days postsurgery. There were difficulties, however, in calculating the time from diagnosis of gastric cancer to liver metastasis. The first time point in this calculation was when the patient received a gastroscopically confirmed diagnosis of gastric cancer, although many had experienced symptoms for some time prior to this. Liver metastasis was diagnosed using ultrasound, CT or MRI, which introduces further uncertainty: metastatic tumours would have been present before this time but would have been undetectable because of their small size. Accordingly, the time from diagnosis of gastric cancer to liver metastasis was not precise, but was the most accurate approximation possible.
There is no standard therapy for liver metastasis arising after resection of primary gastric cancer. TACE has been shown to increase the concentration of chemotherapeutic drugs within the tumour. 27 The present study demonstrated that a large proportion of patients experienced partial remission or stable disease following TACE, and had a median survival of 14.7 months after liver metastasis. Chemotherapeutic extension of survival in patients with unresectable liver metastatic gastric cancer is challenging. Locoregional chemotherapy with combination drugs via TAI has many advantages in patients with liver tumours. TAI, especially when given via the hepatic artery, usually achieves higher therapeutic efficacies and lower toxicities than conventional chemotherapy; this is because the hepatic artery supports 95% of the blood supply to hepatic tumours > 3 mm in diameter, but provides only 25% of the blood supply to normal liver cells. 15, 16 Treatment by TAI with FUDR via the hepatic artery can result in hepatic drug uptake of up to 95%, with tumour drug concentrations shown to be 16 times higher than those achieved by intravenous infusion. 16 In conclusion, the present study demonstrated that TAI chemotherapy is more effective in the prevention of liver metastasis than conventional systemic chemotherapy following gastric adenocarcinoma resection. In addition, TACE was shown to be an effective therapy in patients who went on to develop liver metastasis. These data demonstrate that locoregional TAI chemotherapy may be an effective adjuvant to surgery in the management of liver metastasis resulting from gastric cancer.
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